You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Financial news, mergers and acquisitions, partnerships, and alliances.
The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.
The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.
The MET inhibitor OMO-1 will be studied with Allist's EGFR inhibitor furmonertinib in patients with MET-positive, EGFR-mutated cancers.
The drug giant will be responsible for globally developing and commercializing the compound, called Erso, currently in preclinical development.
The company will use the funds to further develop its proprietary technology for identifying and isolating specific T-cell receptor genes from patients' tumor samples.
